Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
A randomized, open-label, parallel design study in healthy participants to assess the effects of itraconazole and rifampin on the single-dose pharmacokinetics of BMS-986205. Safety and tolerability data to be collected and assessed as well.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
53
PPD
Austin, Texas, United States
Maximum observed plasma concentration (Cmax)
Measured by plasma concentration
Time frame: Up to 25 days
AUC from time zero to time of last quantifiable concentration (AUC(0-T))
Measured by plasma concentration
Time frame: Up to 25 days
AUC from time zero extrapolated to infinite time (AUC(INF))
Measured by plasma concentration
Time frame: Up to 25 days
Incidence of Adverse Events (AEs)
Safety and tolerability as measured by incidence of AEs
Time frame: Up to 25 days
Incidence of Serious Adverse Events (SAEs)
Safety and tolerability as measured by incidence of SAEs
Time frame: Up to 76 days
Number of participants with electrocardiogram abnormalities
Time frame: Up to 25 days
Number of participants with physical examination findings abnormalities
Time frame: Up to 25 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 25 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.